Trial
NCT05501548
Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
AstraZeneca; McGuff Pharmaceuticals, Inc.; The Marcus Foundation
Condition
Prostate Cancer
Intervention
Olaparib
Why stopped
The study was terminated by the IRB due to low accrual,
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-29